Saturday 17 October 2026
Export MLAB’s income statement to Excel — free account
Mesa Laboratories, Inc.
MLAB Technology Scientific & Technical Instruments
Mesa Laboratories, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $249.1 million, up 3.38% from fiscal 2025. In the quarter to June 2026, revenue grew 1.00%, EPS fell 42.5%, free cash flow grew 1,503.7% and total debt rose 70.6%, each against the same quarter a year earlier. Dividend growth for ten consecutive years; insiders bought in the last twelve months.
122.48
5.26
−4.12%
Follow MLAB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 117.16 | 71.89 | 115.76 |
P/S ratio |
1.51 | 1.75 | 1.96 | 2.26 | |
P/FCF ratio |
9.92 | 11.44 | 12.32 | 10.65 | |
P/Operating CF |
44.92 | 23.16 | 34.92 | 38.22 | |
P/B ratio |
2.07 | 2.33 | 2.62 | 2.98 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.14 | 2.31 | 2.46 | 2.70 | |
EV/EBITDA |
13.15 | 13.70 | 14.65 | 14.86 | |
EV/Operating CF |
12.80 | 13.76 | 14.29 | 12.13 | |
EV/FCF |
14.07 | 15.06 | 15.46 | 12.77 | |
Quick Ratio |
1.25 | 1.27 | 1.15 | 1.14 | |
Current Ratio |
2.02 | 1.94 | 1.72 | 1.79 | |
Net Debt/EBITDA |
14.61 | 868.05 | 5.65 | 8.85 | |
Debt/Assets |
40.63% | 38.20% | 35.41% | 34.08% | |
Debt/Equity |
0.98 | 0.89 | 0.81 | 0.76 | |
Asset Turnover |
0.55 | 0.57 | 0.58 | 0.58 | |
Operating CF/Net income |
3.32 | 5.17 | (3.38) | 5.21 | |
Capex/Depreciation |
(0.19) | 0.09 | (0.02) | (0.10) | |
Interest Coverage |
1.65 | 2.63 | 1.06 | 2.98 | |
Research and Development Expense of Revenue |
8.31% | 7.72% | 8.23% | 7.86% | |
Selling, General and Administrative Expense of Revenue |
45.37% | 44.21% | 53.68% | 45.32% | |
Intangible Assets out of Total Assets |
0.65 | 0.64 | 0.63 | 0.63 | |
Share Based Compensation of Revenue |
6.28% | 5.19% | 10.66% | 3.92% | |
Graham Net Nets |
(0.42) | (0.33) | (0.28) | (0.23) | |
Graham Number |
0.00 | 22.56 | 30.57 | 25.41 | |
Earnings Yield |
(0.45%) | 0.85% | 1.39% | 0.86% | |
Free Cash Flow Yield |
10.08% | 8.74% | 8.12% | 9.39% | |
Revenue per Share |
11.02 | 11.77 | 11.56 | 10.63 | |
Operating CF per Share |
1.49 | 3.39 | 2.53 | 2.60 | |
Capex per Share |
(0.20) | (0.13) | (0.08) | (0.10) | |
Free Cash Flow per Share |
1.29 | 3.26 | 2.46 | 2.51 | |
Cash per Share |
3.71 | 5.24 | 4.88 | 5.43 | |
Shareholders Equity per Share |
32.38 | 33.75 | 33.78 | 33.37 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
32.38 | 33.75 | 33.78 | 33.37 | |
Free Cash Flow |
7.13 | 18.02 | 13.55 | 14.18 | |
Working Capital |
49.14 | 51.24 | 44.37 | 45.53 | |
Capital Expenditures |
(1.09) | (0.73) | (0.42) | (0.56) | |
Net Current Asset Value |
(154.45) | (142.53) | (135.23) | (127.62) | |
EV/EBIT |
34.84 | 33.16 | 33.07 | 30.04 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
24.57 | 25.20 | 26.34 | 25.05 | |
| Other line items | |||||
Average Receivables |
40.16 | 39.44 | 43.03 | 36.74 | |
Average Payables |
5.54 | 4.67 | 5.34 | 6.86 | |
Average Inventory |
28.74 | 27.34 | 25.87 | 27.67 | |
Average Assets |
442.22 | 436.00 | 430.55 | 427.48 | |
Average Common Equity |
169.96 | 170.95 | 173.04 | 180.63 |
Columns are period end dates